Update on the Use of Oral Cholera Vaccines (OCV) and Integration with WaSH: Challenges and Opportunities

> Kashmira Date U.S. Centers for Disease Control and Prevention (CDC)

Global Taskforce on Cholera Control (GTFCC) WaSH Working Group Meeting 27 February 2018



Global Immunization Division

Center for Global Health

Outline

- Oral cholera vaccines (OCV) background
- OCV stockpile and Gavi support
- SAGE Recommendation and WHO position update
- OCV use since 2013
- OCV and WaSH integration
 - Related evaluations/studies
 - Challenges
 - Opportunities

Cholera Prevention and Control

Mainstay measures

- Safe water, sanitation and hygiene (WaSH) interventions
- Disease treatment (oral and intravenous rehydration, antibiotics)

Important complementary tool – use in conjunction with mainstay interventions

Oral cholera vaccines (OCVs)

Currently Available and Prequalified OCVs

Euvichol





Shanchol







Main Characteristics: Shanchol and Euvichol

- **Bivalent (O1 and O139), killed whole cell vaccines**
- □ 2 doses, 14 days apart among individuals ≥1 year old
- 1.5 ml volume, no buffer requirement (compared with Dukoral)
- Available through the global OCV stockpile



Shantha/Sanofi (India) Licensed since 2009 (India) Prequalified by WHO in 2011 Multiple studies – good safety, efficacy and field effectiveness, feasibility data 2018 – Prequalified by WHO for controlled temperature chain (CTC) use



Eubiologics (S. Korea) Licensed and prequalified in 2015 Safety and efficacy: noninferiority compared with Shanchol


Global OCV Stockpile

- Sep 2011: WHO consultation called for creation of an OCV stockpile for outbreaks and emergencies
- Jul 2013: Stockpile established for initial 2 million doses through funding from multiple donors
 - Managed by the International Coordinating Group (WHO, UNICEF, MSF and IFRC) similar to other stockpiles
- Nov 2013: Gavi board approved a contribution to the global cholera stockpile during 2014–2018; included funding for operational costs in 2016
- 2014: Establishment of the Gavi OCV subteam and transition to the GTFCC OCV working group (endemic use)

Global OCV Stockpile Requests and Decision Making Mechanism

Emergency stockpile (ICG)

Figure 2- Request process and roles of ICG and partners



Non-emergency reserve

Country Request to GTFCC Secretariat (WHO)

GTFCC OCV working group

Decision by voting (excluding members with conflicts of interest) GTFCC Secretariat Manufacturers

Vaccines in country

Global Recommendations Strategic Advisory Group of Experts on Immunization (SAGE) and WHO Position Paper, 2017

- Implement as a complementary cholera prevention and control measure in the short-to-medium term while access to other primary prevention measures (safe water and sanitation) improve globally
- Given the current availability of killed whole-cell OCVs and data on their safety, efficacy, field effectiveness, feasibility, impact and acceptability in cholera-affected populations, use in different settings in conjunction with WaSH
- Ensure equitable access to the OCV stockpile among populations exposed to the risk of cholera in emergency and endemic settings

Endemic


Epidemic/Outbreak

Humanitarian emergencies

Targeted strategies - Hotspots

Assess risk/risk of spread Determine target areas/populations Assess capacity to implement


Global OCV Use (1)



Source: WHO (Report of the OCV Working Group meeting, Oct 2017

Global OCV Use (2)

Doses shipped by setting since 2013



Row Labels	Sum of Doses requested	Sum of Doses shipped
2013	204,500	204,500
2014	1,962,485	1,486,215
2015	4,219,127	2,302,775
2016	5,021,672	4,645,345
2017	22,040,653	12,049,620
2018	2,301,971	1,406,708
Grand Total	35,750,408	22,095,163

Source: WHO (Dominique Legros)

OCV and WaSH Integration

The Past



PUBLIC HEALTH

No Vaccines in the Time of Cholera

The threat of a major cholera epidemic looms over flood-stricken Pakistan. So why is a new, relatively cheap vaccine unlikely to make a difference?

PUBLIC HEALTH

The Cholera Crisis in Africa

PUBLIC HEALTH

S. Bhattacharya,¹ R. Black,² L. Bourgeois,³ J. Clemens,⁴ A. Cravioto,⁵ J. L. Deen,⁵* Gordon Dougan,⁶ R. Glass,⁷ R. F. Grais,⁸ M. Greco,⁹ I. Gust,¹⁰ J. Holmgren,¹¹ S. Kariuki,¹² P.-H. Lambert,¹³ M. A. Liu,¹⁴ I. Longini,¹⁵ G. B. Nair,¹⁶ R. Norrby,¹⁷ G. J. V. Nossal,¹⁰ P. Ogra,¹⁸ P. Sansonetti,¹⁹ L. von Seidlein,⁵ F. Songane,²⁰ A.-M. Svennerholm,¹¹ D. Steele,³ R. Walker³

Cholera vaccine

plan splits experts

Opinion is divided over how to tackle the disease in Haiti.

Considerations for Oral Cholera Vaccine Use during Outbreak after Earthquake in Haiti, 2010–2011

Summary of Knowledge, Attitudes and Practices Studies

Country	Implementation Setting
Solomon Islands, 2012	Preemptive campaign in response to an outbreak in a nearby region
Haiti, 2012	Campaign in rural Haiti by an NGO (included intense messaging on WaSH)
Haiti, 2013	Government-led campaign in a rural and urban area (limited social mobilization and messaging)
Thailand, 2014	Preemptive campaign by an NGO (included WaSH messaging and subsequent reinforcement of WaSH messaging)

Conclusions

- With careful planning, timing, implementation and messaging, OCV campaigns have the potential to improve WaSH knowledge, attitudes and behaviors
- A potential 'entry point' for further engaging countries and regions in longer term prevention and control efforts

Key Challenges


- Vaccines as "quick fix" lack of need for longer-term, more sustainable approaches
- Where does this belong! Roles and responsibilities for disease prevention and control versus broader wat-san infrastructure management
 - Health ministries communicable diseases, immunization program
 - Non-health ministries wat-san engineering, development
 - Finance ministries
- **Exactly what and how much WaSH is needed?**
 - No one size fits all

Funding


- Gavi support requests (endemic use) at country level through the immunization program – not a priority for the immunization program
- Adequate planning and support for M & E

Opportunities (1)





ENDING CHOLERA A GLOBAL ROADMAP TO 2030



Entran de commun lighten un de less gert mi

casteg ies; bygiene promation , and choies as id, by multilizing community leader, acagent call change

Heith Care System Strengthening interced wade og forchelen autovelg through agacity building for a d Cand pre-pacificating a free succellar d impacting, patient care, and error pencyNR. Solist execution to carfirm a spected case, infam the replace, and that and exclosed castral and elimination

Use of Oral Cholers Vaccine (DCV) Large-code a se of OCV to immediately reduce dissorated a still elas parterin à sien cart ni e novgie: a v pat in place

Opportunities (2)




GLOBAL TASK FORCE ON CHOLERA CONTROL

Cholera Investment Case

Gavi Vaccine Investment Strategy

Figure 5: Investing in the Global Roadmap vs the status quo

Preliminary estimates indicate that the successful implementation of the control strategy may allow up to 50% savings compared to the perpetual average yearly cost of continuously responding to emerging cholera outbreaks with OCV vaccination and a basic minimal package of WASH interventions.





Thank You!

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333 Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Global Immunization Division

Center for Global Health

Dukoral (WC-rBS*)

- Manufactured by Crucell, Sweden
- Monovalent (O1) killed, whole cell oral vaccine mixture of Classic and El Tor strains
- Includes B subunit of cholera toxin: short-term protection against enterotoxigenic *Escherichia coli* (ETEC)
- First licensed in 1991; currently in ~61 countries
- Prequalified by WHO in 2001
- Cost ~ US\$6/dose
 (\$12 \$18 for full schedule
 of 2 3 doses)

* Whole cell, recombinant B-subunit

